We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




HIV Molecule Becomes Cancer-Seeking Trojan Horse

By Biotechdaily staff writers
Posted on 23 Feb 2005
Disguising a disabled HIV molecule in new attire enabled it to track down metastasized melanoma cells in living mice, according to a new study. More...
The researchers added luciferase, the protein that makes fireflies glow, to the virus to track its movement from the bloodstream to new tumors in the mice's lungs.

"For the past 20 years, gene therapy has been hampered by the lack of a good carrier for therapeutic genes that can travel through the blood and aim itself at a precise location, thereby minimizing harmful side effects,” explained Irvin S.Y. Chen, Ph.D., director of the University of California, Los Angeles (UCLA), AIDS Institute (CA, USA). "Our approach proves that it is possible to develop an effective carrier and reprogram it to target specific cells in the body.”

The investigators used a two-step approach to convert the HIV molecule into a cancer-finding missile. They first used a type of HIV from which the viral components that cause AIDS had been taken out. This allowed the virus to infect cells and spread throughout the body without initiating disease.

"The disarmed AIDS virus acts like a Trojan horse--transporting therapeutic agents to a targeted part of the body, such as the lungs, where tumors often spread,” remarked Dr. Chen, a professor of medicine, microbiology, immunology and molecular genetics and a member of the Jonsson Comprehensive Cancer Center at the David Geffen School of Medicine at UCLA.

The second step was to strip off the HIV's viral coat and put on another coat incorporating the Sindbis virus, which typically infects insects and birds. By changing to the Sindbis coat, they reprogrammed the HIV molecule, which usually infects T cells, to track down and attach to P-lipoproteins, molecules situated on the surface of many cancer cells. The UCLA researchers are the first to validate that modified HIV will target and bind with P-gycloproteins.

"P-glycoproteins cause big problems by making the cell resistant to chemotherapy,” said Dr. Chen. "They act like soccer goalies and punt therapeutic drugs out of the cancer cell. This prevents the drug from taking effect and allows the tumor to continue growing unchecked.”

To track the molecule, the investigators injected the HIV molecule into a vein in the mouse's tail and used a special optical camera to track the movement of the luciferase. "The virus traveled through the animal's bloodstream and homed straight to the cancer cells in the lungs, where the melanoma had migrated,” said Dr. Chen.

When the investigators placed the mouse under the camera, the luciferase illuminated the cancer cells, which glowed through the mouse's bones fur, and muscles. The method is noninvasive and does not cause harm or pain to the animal. Although Dr. Chen is excited at proving that HIV can be used to target cancer cells, he cautioned that the approach must be further evaluated for specificity and safety before it can be assessed as a possible gene-based therapy for humans.
.
"Our next step will be to test whether we can direct therapeutic genes to the precise location where cancer cells reside,” Dr. Chen said. "This approach offers many potential applications for controlling cancer and other diseases. We may be able to boost immune-system surveillance at tumor sites, identify cancer cells' exact location, and kill them before they cause damage,” he added. "Beyond cancer, it may be possible to correct acquired and genetic diseases where the mutations exert their harmful effects on the body.”


Related Links:
UCLA AIDS Inst

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.